Decreased Bilirubin is Associated With Disease Activity of Primary Sjögren's Syndrome

Overview

Journal Arch Rheumatol

Specialty Rheumatology

Date 2021 Jan 18

PMID 33458658

Citations 3

Authors

Jing Xie

Zhencheng Zhang

Yan Liang

Zaixing Yang

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aims to determine the serum bilirubin levels in primary Sjögren's syndrome (pSS) patients and to explore clinical significance of bilirubin in pSS.

Patients And Methods: Retrospective analysis of electronic medical records was performed in 97 pSS patients (12 males, 85 females; mean age 54±15 years; range, 15 to 91 years) and 100 healthy controls (17 males, 83 females; mean age 51±14 years; range, 25 to 75 years). Serum bilirubin and other variables were compared between pSS patients and healthy controls. The European League Against Rheumatism Sjögren's syndrome disease activity index (ESSDAI) was used to assess the disease activity of pSS, and ESSDAI ≥5 was defined as moderate to high activity. The relationship between bilirubin and ESSDAI was analyzed by Spearman's correlation analysis and multivariable logistic regression.

Results: The median level of serum bilirubin was 9 μmol/L (interquartile range (IQR), 7-13 μmol/L) in pSS patients, much lower than healthy controls (median, IQR, 13, 10-18 μmol/L) (p<0.001). It was positively correlated with age (r=0.255, p=0.012), but negatively with immunoglobulin (Ig) A (r=-0.314, p=0.003), IgG (r=-0.265, p=0.015), erythrocyte sedimentation rate (r=-0.309, p=0.002) and ESSDAI (r=-0.342, p=0.001). Multivariate analysis revealed that increased bilirubin was independently associated with decreased risk of moderate to high disease activity (odds ratio, 95% confidence interval: 0.852, 0.730-0.955).

Conclusion: Serum bilirubin is decreased in pSS patients and may be a useful biomarker for reflecting pSS disease activity.

Citing Articles

The role of bilirubin as a biomarker of rheumatic diseases: a systematic review and meta-analysis.

Zinellu A, Mangoni A Front Immunol. 2024; 15:1369284.

PMID: 38947324 PMC: 11211262. DOI: 10.3389/fimmu.2024.1369284.

Relationship between bilirubin and systemic lupus erythematosus: A systematic review and meta-analysis.

Yu Y, Wang Q, Zhang D, Wu W, Jiang Z Immun Inflamm Dis. 2023; 11(12):e1115.

PMID: 38156396 PMC: 10739338. DOI: 10.1002/iid3.1115.

Serum bilirubin levels in primary Sjögren's syndrome: an association with interstitial lung disease.

Peng Y, Lu F, Ma L BMC Pulm Med. 2023; 23(1):366.

PMID: 37777728 PMC: 10543857. DOI: 10.1186/s12890-023-02672-5.

References

Juping D, Yuan Y, Shiyong C, Jun L, Xiuxiu Z, Haijian Y . Serum bilirubin and the risk of rheumatoid arthritis. J Clin Lab Anal. 2017; 31(6). PMC: 6817222. DOI: 10.1002/jcla.22118. View

Haga Y, Tempero M, Kay D, Zetterman R . Intracellular accumulation of unconjugated bilirubin inhibits phytohemagglutin-induced proliferation and interleukin-2 production of human lymphocytes. Dig Dis Sci. 1996; 41(7):1468-74. DOI: 10.1007/BF02088574. View

Rocuts F, Zhang X, Yan J, Yue Y, Thomas M, Bach F . Bilirubin promotes de novo generation of T regulatory cells. Cell Transplant. 2009; 19(4):443-51. DOI: 10.3727/096368909X484680. View

Li X, Zhang L, Chen H, Guo K, Yu H, Zhou J . Relationship between serum bilirubin concentrations and diabetic nephropathy in Shanghai Han's patients with type 1 diabetes mellitus. BMC Nephrol. 2017; 18(1):114. PMC: 5376273. DOI: 10.1186/s12882-017-0531-8. View

Longhi M, Vuerich M, Kalbasi A, Kenison J, Yeste A, Csizmadia E . Bilirubin suppresses Th17 immunity in colitis by upregulating CD39. JCI Insight. 2017; 2(9). PMC: 5414551. DOI: 10.1172/jci.insight.92791. View

Peng Y, Zhang L, Pan G, Wei Y . A potential clinical usefulness of measuring serum bilirubin levels in patients with polymyositis. Eur Rev Med Pharmacol Sci. 2016; 20(4):631-5. View

Pagano G, Castello G, Pallardo F . Sjøgren's syndrome-associated oxidative stress and mitochondrial dysfunction: prospects for chemoprevention trials. Free Radic Res. 2012; 47(2):71-3. DOI: 10.3109/10715762.2012.748904. View

Kurimoto C, Kawano S, Tsuji G, Hatachi S, Jikimoto T, Sugiyama D . Thioredoxin may exert a protective effect against tissue damage caused by oxidative stress in salivary glands of patients with Sjögren's syndrome. J Rheumatol. 2007; 34(10):2035-43. View

Basiglio C, Toledo F, Boaglio A, Arriaga S, Ochoa J, Sanchez Pozzi E . Physiological concentrations of unconjugated bilirubin prevent oxidative stress-induced hepatocanalicular dysfunction and cholestasis. Arch Toxicol. 2013; 88(2):501-14. DOI: 10.1007/s00204-013-1143-0. View

10.

Norheim K, Jonsson G, Harboe E, Hanasand M, Goransson L, Omdal R . Oxidative stress, as measured by protein oxidation, is increased in primary Sjøgren's syndrome. Free Radic Res. 2011; 46(2):141-6. DOI: 10.3109/10715762.2011.645206. View

11.

Wu T, Carey D, Wu J, Sugiyama H . The cytoprotective effects of bilirubin and biliverdin on rat hepatocytes and human erythrocytes and the impact of albumin. Biochem Cell Biol. 1991; 69(12):828-34. DOI: 10.1139/o91-123. View

12.

Mariette X, Criswell L . Primary Sjögren's Syndrome. N Engl J Med. 2018; 378(10):931-939. DOI: 10.1056/NEJMcp1702514. View

13.

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos H, Alexander E, Carsons S . Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61(6):554-8. PMC: 1754137. DOI: 10.1136/ard.61.6.554. View

14.

Peng Y, Wang J, Pan G . The correlation of serum bilirubin levels with disease activity in patients with rheumatoid arthritis. Clin Chim Acta. 2017; 469:187-190. DOI: 10.1016/j.cca.2017.04.006. View

15.

Stocker R, Yamamoto Y, McDonagh A, Glazer A, Ames B . Bilirubin is an antioxidant of possible physiological importance. Science. 1987; 235(4792):1043-6. DOI: 10.1126/science.3029864. View

16.

Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A . EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis. 2011; 70(6):968-72. DOI: 10.1136/ard.2010.143743. View

17.

Akboga M, Canpolat U, Sahinarslan A, Alsancak Y, Nurkoc S, Aras D . Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation. Atherosclerosis. 2015; 240(1):110-4. DOI: 10.1016/j.atherosclerosis.2015.02.051. View

18.

Liu Y, Li P, Lu J, Xiong W, Oger J, Tetzlaff W . Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis. J Immunol. 2008; 181(3):1887-97. DOI: 10.4049/jimmunol.181.3.1887. View

19.

Wakamatsu T, Dogru M, Matsumoto Y, Kojima T, Kaido M, Ibrahim O . Evaluation of lipid oxidative stress status in Sjögren syndrome patients. Invest Ophthalmol Vis Sci. 2012; 54(1):201-10. DOI: 10.1167/iovs.12-10325. View

20.

Psianou K, Panagoulias I, Papanastasiou A, de Lastic A, Rodi M, Spantidea P . Clinical and immunological parameters of Sjögren's syndrome. Autoimmun Rev. 2018; 17(10):1053-1064. DOI: 10.1016/j.autrev.2018.05.005. View